Home Brand News Biosimilar Trastuzumab Co-Developed by Biocon Receives Approval in the EU

Biosimilar Trastuzumab Co-Developed by Biocon Receives Approval in the EU

187
0

Ogivri®, a bio-similar Trastuzumab jointly developed by Bio-con and Mylan, has been approved in the EU. The European Commission has granted Marketing Authorization for Ogivri to our partner Mylan.

 

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) previously issued a positive opinion recommending approval of Ogivri as a bio-similar to Roche’s Herceptin® (Trastuzumab) on October 18, 2018.

Ogivri is indicated for the treatment of patients with HER2 positive early breast cancer (EBC), metastatic breast cancer (MBC) and metastatic gastric cancer (MGC). Under supervision of the relevant healthcare professional it can be prescribed as either mono-therapy or in combination with other medicines dependent on the relevant diagnosis.

LEAVE A REPLY

Please enter your comment!
Please enter your name here